[Skip to Content]
[Skip to Content Landing]
Other Articles
June 16, 1951


JAMA. 1951;146(7):655. doi:10.1001/jama.1951.03670070047015

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


The recently concluded two-day meeting of the Subcommittee on Steroids and Cancer at American Medical Association Headquarters demonstrated that the collaborative study sponsored by the Subcommittee has evolved into an efficient reliable method for evaluating cancer therapy. Criteria for selecting cases of mammary cancer to be treated with the hormones, recommendations for optimum dosage schedules, and delineation of the advantages and shortcomings of this form of therapy have evolved as a result of the study, which was begun four years ago. The Subcommittee on Steroids and Cancer is a subcommittee of the Committee on Research of the Council on Pharmacy and Chemistry. At this year's sessions, 64 assembled oncologists initially heard an analysis of the pooled results of their reports to the Committee on Research and then engaged in panel discussion of the mechanism of action of the steroid hormones in mammary cancer. On the second day, the influence of

First Page Preview View Large
First page PDF preview
First page PDF preview